Cue Biopharma (CUE) - Total Liabilities
Based on the latest financial reports, Cue Biopharma (CUE) has total liabilities worth $18.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Cue Biopharma to evaluate the company's liquid asset resilience ratio.
Cue Biopharma - Total Liabilities Trend (2015–2024)
This chart illustrates how Cue Biopharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Cue Biopharma.
Cue Biopharma Competitors by Total Liabilities
The table below lists competitors of Cue Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Syntara Ltd
AU:SNT
|
Australia | AU$5.42 Million |
|
Pennon Group Plc
LSE:PNN
|
UK | GBX6.07 Billion |
|
Romcarbon Sa B
RO:ROCE
|
Romania | RON152.62 Million |
|
Sangji Caelum Inc
KQ:042940
|
Korea | ₩117.19 Billion |
|
Take Solutions Limited
NSE:TAKE
|
India | Rs95.84 Million |
|
Salee Industry Public Company Limited
BK:SALEE
|
Thailand | ฿269.25 Million |
|
KPS Consortium Bhd
KLSE:9121
|
Malaysia | RM257.16 Million |
|
Inmobiliaria Park Rose Iberoamericana SOCIMI SA
MC:YPARK
|
Spain | €11.04 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Cue Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Cue Biopharma to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cue Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cue Biopharma (2015–2024)
The table below shows the annual total liabilities of Cue Biopharma from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.69 Million | -39.90% |
| 2023-12-31 | $24.45 Million | -4.52% |
| 2022-12-31 | $25.60 Million | +42.95% |
| 2021-12-31 | $17.91 Million | -13.16% |
| 2020-12-31 | $20.62 Million | +21.16% |
| 2019-12-31 | $17.02 Million | +49.42% |
| 2018-12-31 | $11.39 Million | +113.06% |
| 2017-12-31 | $5.35 Million | +384.31% |
| 2016-12-31 | $1.10 Million | +193.38% |
| 2015-12-31 | $376.30K | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more